BMS-986165

Product Name: BMS-986165
CAS No.: 1802425-99-5
Chemical Name: BMS-986165
Synonyms: BMS-986177;BMS-986165;JNJ-70033093;Milvexian (BMS-986177);Milvexian, BMS-986177 , JNJ-70033093;11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one, 10-[4-[5-chloro-2-(4-chloro-1;(9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one;(6R,10S)-10-[4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one;11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one, 10-[4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-;11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one,10-[4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyChemicalbookl-,(6R,10S)-
CBNumber: CB28108731
Molecular Formula: C28H23Cl2F2N9O2
Formula Weight: 626.45
MOL File: 1802425-99-5.mol

More

Less

BMS-986165 Property

Density: 1.60±0.1 g/cm3(Predicted)
storage temp.: Store at -20°C
form: Solid
pka: 13.42±0.60(Predicted)
color: White to off-white
InChIKey: FSWFYCYPTDLKON-FRHUOMFCNA-N
SMILES: C(N1N=CC2NC([C@@H](CCC[C@H](N3C=NC(C4C=C(Cl)C=CC=4N4N=NC(Cl)=C4)=CC3=O)C3N=CC=C(C=3)C1=2)C)=O)(F)F |&1:7,11,r|

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

BMS-986165 Chemical Properties,Usage,Production

Uses

Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study[1].

in vivo

Milvexian (20 mg/kg for PO) produces average plasma concentrations of 2000 and 40 nM at 1 and 24 h after dosing, respectively^[1].
Milvexian (0.8 mg/kg for i.v.) produces average plasma concentrations of 2000 and 100 nM at 10 min and 8 h after dosing, respectively^[1].
Milvexian (0.063-4 + 0.04- 2.68 mg/kg for i.v. plus a continuous infusion) inhibites the formation of thrombosis in vivo^[2].

Pharmacokinetic Analysis in Rabbits^[1]

Route	Dose (mg/kg)	Clearance (mL/min/kg)	Volume of Distribution (L/kgL)	Half-life (h)	Oral Bioavailability (%)
i.v./p.o.	0.8/20	6.7	1.4	2.5	14

Animal Model:	The rabbit electrically mediated carotid arterial thrombosis model^[1]
Dosage:	Prevention: 0.063 + 0.04, 0.25 + 0.17, and 1 + 0.67 (mg/kg + mg/kg/h) Treatment: 0.25 + 0.17, and 1 + 0.67 (mg/kg + mg/kg/h)
Administration:	Intravenous injection (i.v.) plus a continuous infusion
Result:	Decreased carotid blood flow(CBF) to 32-76% and reduced thrombus weight by 15-70%. Decreased CBF to 40% of control initiated after 15 min. Decreased CBF to 39-66% after Seventy-five minutes.

Animal Model:	The rabbit cuticle bleeding time model^[1]
Dosage:	Prevention: 0.063 + 0.04, 0.25 + 0.17, and 1 + 0.67 (mg/kg + mg/kg/h) Prevention: 0.063 + 0.04, 0.25 + 0.17, and 1 + 0.67 (mg/kg + mg/kg/h) Treatment: 0.25 + 0.17, and 1 + 0.67 (mg/kg + mg/kg/h)
Administration:	Intravenous injection (i.v.) plus a continuous infusion
Result:	Did not increase the carotid blood flow(BT) with combination of Aspirin (HY-14654).

Animal Model:	The rabbit arteriovenous shunt model^[2]
Dosage:	Prevention: 0.063 + 0.04, 0.25 + 0.17, and 1 + 0.67 (mg/kg + mg/kg/h) Prevention: 0.063 + 0.04, 0.25 + 0.17, and 1 + 0.67 (mg/kg + mg/kg/h) 0.25?+?0.17, 1.0?+?0.67, and 4.0?+?2.68 ?mg/kg
Administration:	Intravenous injection (i.v.) plus a continuous infusion
Result:	Reduced thrombus weight of thrombosis by 34.3?-66.9?%. Increased the prolongation of APTT with 1.54-3.12-fold, but did not alter the PT and TT.

References

[1] Pancras C. Wong, et al. Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
[2] Xinkang Wang, et al. Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis. TH Open. 2023 Apr; 7(2): e97–e104.
[3] Wong P, et al. Small-Molecule Factor XIa Inhibitor, BMS-986177/JNJ-70033093, Prevents and Treats Arterial Thrombosis in Rabbits at Doses that Preserve Hemostasis [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1).

BMS-986165 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

BMS-986165 Suppliers

China 53 India 2 Global 55

Foshan Junzheng Biotechnology Co., Ltd

Tel: 17813018085
Email: 181367029@qq.com
Country: China
ProdList: 62
Advantage: 58

ChengDu TongChuangYuan Pharmaceutical Co.Ltd

Tel: 028-83379370 13880556291
Fax: 028-87747383
Email: tcy@tcypharm.com
Country: China
ProdList: 7218
Advantage: 58

Bayee Biotech (Anqing) Co., Ltd.

Tel: 0556-5032306 18917961636
Email: wtx@bayeebio.com
Country: China
ProdList: 239
Advantage: 61

Taizhou Nanfeng Pharmaceutical Research Institute

Tel: nanfengdrug@163.com; 18616377689
Email: nanfengdrug@163.com
Country: China
ProdList: 20009
Advantage: 58

Block Chemical Technology (Shanghai) Co., LTD

Tel: 021-20432219 13918097649
Fax: QQ79021576
Email: li_jinfei@acblock-lab.com
Country: China
ProdList: 9673
Advantage: 58

Anhui nuoquan pharmaceutical co. LTD

Tel: 15705561919
Fax: 0556-5032869
Email: chunli.yi@nuozhanchem.com
Country: China
ProdList: 101
Advantage: 55

ShangHai Caerulum Pharma Discovery Co., Ltd.

Tel: 18149758185
Email: sales-cpd@caerulumpharma.com
Country: China
ProdList: 3506
Advantage: 58

Shanghai Lollane Biological Technology Co.,Ltd.

Tel: 021-52996696，15000506266 15000506266
Fax: +86-21-52996696
Country: China
ProdList: 4768
Advantage: 55

Shanghai Haozhixiang Biotechnology Co., Ltd

Tel: 526763801 13301653310
Fax: +86-21-51619052
Email: 526763801@qq.com
Country: China
ProdList: 9287
Advantage: 55

Cangzhou Enke Pharma-tech Co., Ltd.

Tel: 0317-5296180 15533709196
Fax: 0317-5106596
Email: sale@enkepharma.com
Country: China
ProdList: 2267
Advantage: 55

More

Less

View Lastest Price from BMS-986165 manufacturers

Shanghai Joiny Pharmaceutical Co.,LTD

Product: Milvexian 1802425-99-5
Price: US $0.00/kg
Min. Order: 1kg
Purity: 98%
Supply Ability: 1000kg
Release date: 2025-11-07

1802425-99-5, BMS-986165Related Search:

11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one, 10-[4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-

BMS-986177

11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one, 10-[4-[5-chloro-2-(4-chloro-1

JNJ-70033093

Milvexian, BMS-986177 , JNJ-70033093

BMS-986165

Milvexian (BMS-986177)

(9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one

11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one,10-[4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyChemicalbookl-,(6R,10S)-

(6R,10S)-10-[4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one

1802425-99-5

C28H23Cl2F2N9O2